In summary, these data showed that continued use of trastuzumab in PTEN-deficient breast cancer induces a transition between mesenchymal- and epithelial-like BCSC states and transforms luminal HER2+ cells to a basal like phenotype. This evidence concerns the gene PTEN and breast carcinoma.